Clinical trials: Bacterial Diseases
Hepatitis B, Polio
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule
To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series.
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00315055
- Testing
- DTaP-IPV-HB-PRP~T vaccine, DTaP-IPV//PRP~T combined, Hepatitis B vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
- Trial name
- NCT04553406
- Testing
- SPR720, Open-label Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Spero Therapeutics
Gonorrhea, Meningococcal Disease
Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)
This study aims to implement a targeted 4CMenB immunisation program in young people aged 14-19 years in the Northern Territory (NT).
- Trial name
- NCT04398849
- Testing
- Licenced 4CMenB Vaccine
- Where
- Australia
- Volunteers
- 7,100 people, healthy volunteers welcome
- Sponsor
- University of Adelaide
Tuberculosis
Tuberculosis Immunity in Children
The purpose of this study is to gain a better understanding of how immunity to tuberculosis (TB) is maintained in children. When children get tuberculosis, it is more likely to spread to other parts of the body than when adults…
- Trial name
- NCT00170638
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diphtheria, Tetanus
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
This study will evaluate immunogenicity, safety and tolerability of fully liquid pentavalent vaccine (DTwP-Hib-HepB Vaccine) in infants 6-8 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT01470287
- Testing
- DTwP-HepB-Hib Vaccine
- Where
- 3 sites in India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Ocular Histoplasmosis
Treatment for Presumed Ocular Histoplasmosis
The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.
- Trial name
- HANDLE (NCT01790893)
- Testing
- aflibercept
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- John Kitchens, MD
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.
- Conditions
- Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection
- Trial name
- OPTIMAL (NCT06817421)
- Testing
- Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
- Where
- Timor-Leste
- Volunteers
- 214 people
- Sponsor
- Nick Fancourt
Rheumatic Heart Disease
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
GOAL-Stop is a randomized, controlled, non-inferiority trial designed to evaluate whether discontinuing secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression of rheumatic heart disease…
- Trial name
- GOAL-Stop (NCT07146048)
- Testing
- Secondary Prophylaxis
- Where
- Uganda
- Volunteers
- 922 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Neurosyphilis
Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis
A retro-prospective case-control Swiss study was conducted to evaluate the diagnostic performance of measuring an antibody index (AI) for intrathecal synthesis of specific anti-Treponema pallidum (T.
- Trial name
- NCT06152393
- Testing
- Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.
- Where
- Switzerland
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Haemophilus Influenzae Type b (Hib) Infection
Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China
This study will evaluate the safety and efficacy of two doses of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 6-12 months of age.
- Trial name
- NCT01044316
- Testing
- Haemophilus influenzae type b (Hib) vaccine
- Where
- China
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Campylobacter Infection
ACE393-103 Vaccination Challenge Study
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
- Trial name
- ACE393-103VC (NCT00859716)
- Testing
- ACE393
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Tetanus, Diphtheria and Acellular Pertussis Vaccination
Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors
The goal of this clinical trial is to investigate the safety and tetanus antibody response to a Tdap vaccine in healthy plasma donors.
- Trial name
- NCT05662852
- Testing
- Tdap
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- ABO Holdings, Inc.
Mycobacterium Infections, Tuberculosis
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
Background: Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches.
- Conditions
- Mycobacterium Infections, Tuberculosis, Filariasis, Latent Tuberculosis
- Trial name
- NCT01547884
- Where
- 2 sites in United States, India
- Volunteers
- 4,268 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Abscess, Skin Diseases, Infectious
Study of Wound Packing After Superficial Skin Abscess Drainage
Superficial skin and soft tissue abscess are frequently managed by opening them up with a procedure called "incision and drainage".
- Conditions
- Abscess, Skin Diseases, Infectious, Boils, Furuncle
- Trial name
- NCT00746109
- Testing
- Wound packing, NoPacking
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response…
- Trial name
- NCT05138822
- Testing
- GSK3882347, Nitrofurantoin
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical…
- Conditions
- Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections
- Trial name
- CaspoNEB (NCT06892951)
- Testing
- Caspofungin Acetate 50 MG, Physiologic saline
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Tours
Urinary Tract Infection
The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
The SCOUT study is a multi-center, centrally randomized, double-blind, placebo-controlled non-inferiority clinical trial. 746 participants will be enrolled over a 4.5 year period.
- Trial name
- NCT01595529
- Testing
- Cefixime, Cephalexin, Trimethoprim/Sulfamethoxazole
- Where
- United States
- Volunteers
- 717 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection
To compare the positivity rate of the investigational assay to the currently approved QuantiFERON-TB Gold In-Tube assay.
- Trial name
- NCT02687529
- Testing
- CST001
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Cystic Fibrosis, Pseudomonas Aeruginosa
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic candidate administered…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection
- Trial name
- SWARM-Pa (NCT04596319)
- Testing
- AP-PA02
- Where
- 20 sites in United States
- Volunteers
- 29 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.